esophageal cancer, gastric cancer, colorectal cancer
Conditions
Interventions
Gold Standard:Endoscopic combined with pathological examination results
Sponsors
The Second Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Gastrointestinal Malignant Tumor Group (1) Between the ages of 20 (inclusive) and 80 (inclusive), both male and female; (2) Patients with gastrointestinal malignancies such as esophageal cancer, gastric cancer, and colorectal cancer were first diagnosed by histopathological examination; (3) Did not receive any form of treatment (including surgery, radiotherapy, chemotherapy and immunotherapy, etc.) before peripheral blood sample collection; (4) It can provide complete medical history and complete postoperative pathological information. Non-cancer group of digestive tract (1) Between the ages of 20 (inclusive) and 80 (inclusive), both male and female; (2) Patients confirmed by histopathological examination as polyps, gastritis, ulcers and other non-cancer diseases of the digestive tract; (3) Did not receive any form of treatment (including surgery, radiotherapy, chemotherapy and immunotherapy, etc.) before peripheral blood sample collection; (4) It can provide complete medical history and complete postoperative pathological information. Group of healthy controls (1) Between the ages of 20 (inclusive) and 80 (inclusive), both male and female; (2) Colonoscopy report indicated no obvious abnormality; (3) The subject can provide a complete disease history.
Exclusion criteria
Exclusion criteria: Gastrointestinal Malignant Tumor Group (1) Patients with malignant lymphoma, neuroendocrine carcinoma, carcinoid, etc.; (2) the combination of any malignant tumor at any site other than the primary site of malignant tumor or any previous malignant tumor; (3) Diseases complicated with autoimmune diseases, acute/chronic infections, lymphoma and other diseases that may affect the expression and function of PBMCs in the body; (4) Patients who have received allogeneic blood transfusion or immune cell therapy within 1 year; (5) Blood samples are contaminated or appear hemolysis, lipemia and other phenomena. Non-cancer group of digestive tract (1) Serological or imaging findings indicate malignant tumors at any site; (2) Autoimmune diseases, acute/chronic infections, lymphoma and other immune diseases; (3) Patients who have received allogeneic blood transfusion or immune cell therapy within 1 year; (4) Laboratory examination results indicate abnormal function of major organs, liver and kidney; (5) Women who are pregnant or breastfeeding; (6) The peripheral blood sample is unqualified, and the phenomenon of hemolysis and lipemia occurs. Group of healthy controls (1) Serological or imaging findings indicate malignant tumors at any site; (2) Autoimmune diseases, acute/chronic infections, lymphoma and other immune diseases; (3) Patients who have received allogeneic blood transfusion or immune cell therapy within 1 year; (4) Laboratory examination results indicate abnormal function of major organs, liver and kidney; (5) Women who are pregnant or breastfeeding; (6) The peripheral blood sample is unqualified, and the phenomenon of hemolysis and lipemia occurs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Curve (AUC);sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Specificity;Positive Predictive Value (PPV);Negative Predictive Value (NPV); | — |
Countries
China
Contacts
Public ContactWang Chuanxin
The Second Hospital of Shandong University
Outcome results
None listed